Revelyx Bio key facts
as of Oct 2026- Developer of a botulinum toxin liquid formulation designed to bring a new anti-aging and medical experience characterized by efficacy.
- Revelyx Bio is valued at approximately $109.5M as of Oct 2026 (last reported valuation).
- It has raised $10.4M; the latest was Early Stage VC ($10.0M) in Jan 2026.
- Notable investors include NRL Capital.
- Status: Privately Held (backing).
Revelyx Bio's last reported valuation, Jan 2026. Nothing priced has surfaced since.
- ·Watch Revelyx Bio: the Monday email on marks, rounds and moves
Revelyx Bio funding rounds
No funding rounds for Revelyx Bio are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
Who backs Revelyx Bio
1Revelyx Bio valuation
Revelyx Bio's last reported valuation was $110 million in Jan 2026. No priced round, secondary trade or fund mark has surfaced since.
Revelyx Bio investors
1 investor is on record for Revelyx Bio, including NRL Capital.
About Revelyx Bio
Developer of a botulinum toxin liquid formulation designed to bring a new anti-aging and medical experience characterized by efficacy. The company's formulation is low immunogenicity, overcomes drug resistance, has precise targeting, and user-friendly.
- Sector
- Healthcare
- HQ
- DE
- Founded
- 2025
- Ownership
- Privately Held (backing)
Is this your company? Sign in with your work email to keep it current, or tell us what's wrong.